Two Technical Setups with Quality Fundamental Backstories
Research - Two technical trade ideas, both names PropThink has followed for some time, with quality, fundamental backstories.
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Stem Cells Get a Break with StemCells’ Early AMD Results
Insights - StemCells, Inc. (STEM) announced on Thursday interim results from a phase 1/2 trial of its HuCNS-SC cells in dry age-related macular degeneration (AMD). The results are encouraging in a field that has … Continue Reading
Read now
Insmed Gets Breakthrough Designation Based on Failed Study
Insights - Insmed (INSM) announced on Wednesday that the FDA has granted Arikayce (liposomal amikacin), the company’s lead product candidate, Breakthrough Therapy Designation (BTD) for refractory nontuberculous mycobacterial (NTM) lung … Continue Reading
Read now
Investor Beware: Vivus Buyout Bid Fails to Materialize
Insights - It’s June 18, five days past a self-imposed deadline, and Aspen Investment Fund is nowhere to be seen with its alleged $640 million bid to buy Vivus, Inc. … Continue Reading
Read now
Don’t Misunderstand EnteroMedics’ Positive Panel Vote
Insights - The U.S. FDA’s Advisory Gastroenterology and Urology Devices Panel (GUDP) voted on Tuesday 6 to 2 (one abstention) that the relative benefits of EnteroMedics’ (ETRM) VBLOC vagal blocking … Continue Reading
Read now
Flamel Shakes Off Drug Rejection, Sets up Big Event for August
Insights - Flamel (FLML) quickly turned around a CRL received in late April for one of its pipeline drug candidates. That sets up a big event for August 6.
Read now
Takeover Fever Struck Achillion, but AbbVie’s Still Way Out in Front
Insights - Achillion Pharmaceuticals (ACHN) has been all over the news in the last week (and up more than 100%), the latest target of takeover fever in … Continue Reading
Read now